Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

NCT07292012 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Crohn Disease (CD)

Interventions

DRUG: Mirikizumab - IV
DRUG: Mirikizumab - SC

Sponsor

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives